Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Teva Launches First Generic Version of Sandostatin® LAR Depot in The U.S.
Details : Sandostatin-Generic (octreotide acetate) is a somatostatin analogue peptide, which is being evaluated for the treatment of acromegaly, carcinoid tumors & vasoactive intestinal peptide tumors.
Brand Name : Sandostatin-Generic
Molecule Type : Peptide
Upfront Cash : Not Applicable
October 01, 2024
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Camurus Reports Positive Phase 3 Results for CAM2029 in Acromegaly
Details : CAM2029 (octreotide) is a ready-to-use octreotide for subcutaneous administration under development for treatment of acromegaly as well as GEP-NET and polycystic liver disease (PLD).
Brand Name : CAM2029
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 15, 2024
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Aspen Pharmacare Holdings
Deal Size : $99.9 million
Deal Type : Agreement
Aspen Concludes Two Significant Agreements with Sandoz for China and Europe
Details : The agreements aim to support Aspen for commercialization of Sandostatin LAR Depot (octreotide acetate), which is indicated for long-term treatment of acromegaly & severe diarrhea and flushing episodes associated with metastatic carcinoid tumors.
Brand Name : Sandostatin LAR Depot
Molecule Type : Peptide
Upfront Cash : Undisclosed
December 04, 2023
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Aspen Pharmacare Holdings
Deal Size : $99.9 million
Deal Type : Agreement
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : CAM2029 is a ready-to-use octreotide for subcutaneous administration under development for treatment of acromegaly as well as gastroenteropancreatic neuroendocrine tumors (GEP-NET), and polycystic liver disease (PLD).
Brand Name : CAM2029
Molecule Type : Peptide
Upfront Cash : Not Applicable
July 17, 2023
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate,Lanreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Debio 4126 (octreotide) is a synthetic octapeptide that mimics the pharmacology of endogenous somatostatin (SST). It demonstrates activity against growth hormone and glucagon, treating the disordered tissue growth and insulin regulation in patients with ...
Brand Name : Debio 4126
Molecule Type : Peptide
Upfront Cash : Not Applicable
January 12, 2023
Lead Product(s) : Octreotide Acetate,Lanreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Oncology
Study Phase : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Details : Mycapssa® (oral octreotide) is approved by the FDA and the EC for long-term maintenance treatment in acromegaly patients who have responded to and tolerated injectable treatment with octreotide or lanreotide (i.e. somatostatin analogs (SSAs)).
Brand Name : Mycapssa
Molecule Type : Peptide
Upfront Cash : Not Applicable
December 19, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Oncology
Highest Development Status : Phase I
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
European Commission Approves Mycapssa® For the Treatment of Acromegaly
Details : Mycapssa (octreotide) is an oral prescription medicine used in the long-term maintenance treatment of acromegaly in people for whom initial treatment with octreotide or lanreotide has been effective and tolerated.
Brand Name : Mycapssa
Molecule Type : Peptide
Upfront Cash : Not Applicable
December 05, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amryt Announces New Patent for Mycapssa®
Details : Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Brand Name : Mycapssa
Molecule Type : Peptide
Upfront Cash : Not Applicable
November 30, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
CHMP Adopts Positive Opinion for Mycapssa® for the Treatment of Acromegaly
Details : 91% of patients on Mycapssa® (octreotide) maintained IGF-1 response (95% CI 44-53), throughout the RCT, compared to 100% on iSRLs (95% CI 34-37). Response was defined as the time-weighted average of IGF-1 <1.3 x upper limit of normal (ULN) during the 9-...
Brand Name : Mycapssa
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 16, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Phase III
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Study Phase : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
Amryt Announces New Patent for Mycapssa®
Details : Mycapssa® (octreotide capsules) is approved in the US for long-term maintenance therapy in acromegaly patients who have responded to and tolerated treatment with octreotide or lanreotide.
Brand Name : Mycapssa
Molecule Type : Peptide
Upfront Cash : Not Applicable
September 13, 2022
Lead Product(s) : Octreotide Acetate
Therapeutic Area : Endocrinology
Highest Development Status : Approved
Sponsor : Not Applicable
Deal Size : Not Applicable
Deal Type : Not Applicable
LOOKING FOR A SUPPLIER?